Yes. As of September 2026, Stryker Corporation (SYK) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.91% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 13.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.85% / 33% · Receivables / Mkt Cap (36m) 3.22% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 13.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.85% / 33.33% · Receivables / Mkt Cap (24m) 3.22% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 32.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.30% / 33.33% · Receivables / Avg Assets (4Q) 7.95% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 31.9% / 33.33% · (Cash+ST Inv) / Total Assets 6.92% / 33.33% · (Cash+Recv) / Total Assets 14.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Stryker Corporation (SYK) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
Yes. Stryker Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Stryker Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Stryker Corporation (NYSE: SYK) is a Healthcare company (Medical - Devices) with a market capitalization of $118.3B. The Maz Rating grades it against the other companies in its sector.
Stryker Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $310.72, Stryker Corporation trades at 32.9x trailing earnings, 4.5x sales and 5.1x book value, with an EV/EBITDA of 19.7. Over the last twelve months it generated about $26.3B of revenue and $3.6B of net income. It runs a gross margin of 65.5%, an operating margin of 21.3% and a net margin of 13.8%. It shows return on equity of 15.6%, return on invested capital of 9.5% and a free cash flow yield of 3.9%. On the balance sheet: a debt-to-equity ratio of 0.66 and a current ratio of 2.18. Over the past 52 weeks the share price ranged from $267.00 to $389.33, with a beta of 0.78.
Stryker Corporation pays a dividend yielding 1.13%, with 37% of earnings paid out. Its Maz Dividend Score is 3.30 out of 5, ranked against the other dividend payers in its sector (Safety 2.70, Growth 3.50, Yield 2.77, Consistency 3.95).
52 Wall Street analyst ratings cover the stock: 1 Strong Buy, 35 Buy and 16 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.